РОЛЬ КИНЕТИЧЕСКИХ ХАРАКТЕРИСТИК ПРОСТАТОСПЕЦИФИЧЕСКОГО АНТИГЕНА ПРИ ОТБОРЕ ПАЦИЕНТОВ ДЛЯ ПРОВЕДЕНИЯ¹¹C-ХОЛИН-ПОЗИТРОННО-ЭМИССИОННОЙ ТОМОГРАФИИ ДЛЯ ВЫЯВЛЕНИЯ МЕСТНЫХ РЕЦИДИВОВ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ

Given study was aimed to research a role of kinetic performance of PSA in selection of the patients for conduction ¹¹C-choline PET/CT in order to reveal local recurrences in patient with prostate cancer after radiation therapy (RT) and radical prostatectomy (RP). The study included 185 patients with histologically distinctive prostate cancer and biochemical signs of tumor recurrence after RP (61 patients) or RT (124 patients). All the patients were examined using ¹¹C-choline PET/ CT in order to detect local relapses. Calculation of growth rate of the PSA level and PSA doubling time were made. According to results of ¹¹C-choline PET/CT, recurrences of prostate cancer were detected in 124 out of 185 (65%). There were 22 patients out of 61 (36%) after RP and there were 102 patients out of 124 (82%) after RT. It was stated a correlation between PSA rates, growth rate of PSA level and presence or absence of relapse according to PET/CT results. PSA level and growth rate of PSA were indicated as the most significant predictive signs, which could influence on the selection of the patients for conduction of ¹¹C-choline PET/CT in relation to detection of local recurrence after RT and RP.

простатоспецифический антиген, кинетические характеристики, рак предстательной железы, позитронно-эмиссионная томография, компьютерная томография, радиотерапия, радикальная простатэктомия, местные рецидивы

1. Breeuwsma A. J., Pruim J., Van Den Bergh A. C. M. et al. Detection of local, regional and distant recurrence in patients with PSA relapse after external beam radiotherapy using (11)C-choline positron emission tomography // Int. J. Radiat. Oncol. Biol. Phys. 2010. Vol. 77. P. 160-164.

2. Castellucci P., Fuccio C., Nanni C. et al. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy // J. Nucl. Med. 2009. Vol. 50. P. 1394-1400.

3. Castellucci P., Picchio M. 11C-choline PET/CT and PSA kinetics // Eur. J. Nucl. Med. Mol. Imaging. 2013. Vol. 40. Suppl 1. P. S36-40.

4. Consensus statement. Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel // Int. J. Radiat. Oncol. Biol. Phys. 1997. Vol. 37. P. 1035-1041.

5. de Jong I. J., Pruim J., Elsinga P. H. et al. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer // Eur. Urol. 2003. Vol. 44. P. 32-38.

6. Dusing R. W., Peng W., Lai S. M. et al. Prostate-specific antigen and prostate-specific antigen velocity as threshold indicators in 11C-acetate PET/CTAC scanning for prostate cancer recurrence // Clin. Nucl. Med. 2014. Vol. 39. № 9. P. 777-783.

7. Fitzpatrick J. M., Banu E., Oudard S. Prostate-specific antigen kinetics in localized and advanced prostate cancer // BJU Int. 2009. Vol. 103. P. 578-587.

8. Giovacchini G., Picchio M., Scattoni V. et al. PSA doubling time for prediction of 11C-choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy // Eur. J. Nucl. Med. Mol. Imaging. 2010. Vol. 37. P. 1106-1116.

9. Graute V., Jansen N., Ubleis C. et al. Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy // Eur. J. Nucl. Med. Mol. Imaging. 2012. Vol. 39. № 2. P. 271-282.

10. Han M., Partin A. W., Pound C. R. et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience // Urol. Clin. North Am. 2001. Vol. 28. P. 555-565.

11. Hara T. 11C-choline and 2-deoxy-2-[18F]fluoro-D-glucose in tumor imaging with positron emission tomography // Mol. Imaging Biol. 2002. Vol. 4. P. 267-273.

12. Krause B. J., Souvatzoglou M., Tuncel M. et al. The detection rate of [(11)C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer // Eur. J. Nucl. Med. Mol. Imaging. 2008. Vol. 35. P. 18-23.

13. Maffezzini M., Bossi A., Collette L. Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer // Eur. Urol. 2007. Vol. 51. P. 605-613.

14. Palma D., Tyldesley S., Pickles T. Prostate Cohort Outcomes Initiative. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy // Cancer. 2008. Vol. 112. P. 1941-1948.

15. Petit J. H., Chen M. H., Loffredo M. et al. Prostate-specific antigen recurrence and mortality after conventional dose radiation therapy in select men with low-risk prostate cancer // Cancer. 2006. Vol. 107. P. 2180-2185.

16. Picchio M., Messa C., Landoni C. et al. Value of 11C choline-positron emission tomography for restaging prostate cancer: a comparison with 18F fluorodeoxyglucose-positron emission tomography // J. Urol. 2003. Vol. 169. P. 1337-1340.

17. Rinnab L., Mottaghy F. M., Blumstein N. M. et al. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer // BJU Int. 2007. Vol. 100. P. 786-793.

18. Zagars G. K. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy // J. Urol. 1994. Vol. 152. P. 1786-1791.